Metsera (NASDAQ:MTSR) shares opened at $25.50 after being priced at $18 per share, later hitting a high of $28.87. The stock recently sold for $27.75 at around 12:45 p.m. ET. The drug developer pr ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...

With the completion of our recent IPO, we have substantial capital to ... as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli Lilly (NYSE:LLY) on Thursday after the Indiana-based pharma giant reported ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

In February, Metsera completed an IPO, raising approximately $316.2 million in aggregate gross proceeds from the offering before deducting underwriting discounts, commissions and other offering ...